Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/annrheumdis-2021-220756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinct tropisms of HCMV and SARS-CoV-2 in lung tissue of a patient with advanced HIV disease.
Virol Sin
January 2025
Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Electronic address:
A serial case report of hospitalized patients with Creutzfeldt-Jakob disease due to coronavirus disease (COVID)-19 in Brazil: A four-year profile.
J Neurol Sci
January 2025
Laboratory of Molecular Biology and Genetics, Postgraduate Program of Health Sciences, São Francisco University, Bragança Paulista, São Paulo, Brazil; Laboratory of Clinical and Molecular Microbiology, Postgraduate Program of Health Sciences, São Francisco University, Bragança Paulista, São Paulo, Brazil; LunGuardian Research Group - Epidemiology of Respiratory and Infectious Diseases, Postgraduate Program of Health Sciences, São Francisco University, Bragança Paulista, São Paulo, Brazil. Electronic address:
Time matters in therapeutic plasma exchange for improving outcomes in severe COVID-19.
Ther Apher Dial
January 2025
Department of Pediatric Intensive Care Medicine, Life Support Center, Hacettepe University, Ankara, Türkiye.
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders.
Vaccine
December 2024
University Department of Child and Adolescent Psychiatry, Children's Hospitals of Nice, CHU-Lenval, Nice, France; CoBTek, Université Côte d'Azur, Nice, France; Filière de santé maladies rares (FSMR) DéfiScience, Centre de Référence constitutif Maladies Rares à expression psychiatrique (PsyRare) de Nice.
COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.
Rheumatol Int
December 2024
Department of General Practice N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!